Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia

Jacobs, Victoria; Woller, Scott C.; Stevens, Scott M.; May, Heidi T.; Bair, Tami L; Anderson, Jeffrey L.; Crandall, Brian G.; Day, John D.; Johanning, Katie; Long, Yenh; Mallender, Charles; Olson, Jeffrey L.; Osborn, Jeffrey S.; Weiss, J. Peter; Bunch, T. Jared

doi:10.1016/j.hrthm.2014.08.013

Cited by 141 publications

(108 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One recent study proved that among 2605 AF patients treated with warfarin, the quality of anticoagulation, expressed in terms of time in the therapeutic range, was indeed associated with incident dementia. 40 Now that also newer oral anticoagulants are available, possible differences in terms of cognitive outcomes should be tested across these drugs and in comparison with warfarin.…”

Section: May the Relation Between Af And Cognitive Impairment Affect mentioning

confidence: 99%

Atrial Fibrillation and Cognition

Poggesi

Inzitari

Pantoni

2015

Stroke

View full text Add to dashboard Cite

Section: May the Relation Between Af And Cognitive Impairment Affect mentioning

confidence: 99%

Atrial Fibrillation and Cognition

Poggesi

Inzitari

Pantoni

2015

Stroke

View full text Add to dashboard Cite

“…Hallmarks of AD neuropathology are accumulation of extracellular amyloid-␤ (A␤) in senile plaques, intraneuronal phosphorylated tau proteins in tangles, and activation of microglial cells [1]. In addition to age, acquired cardiovascular disorders, such as mid-life hypertension [2], diabetes [3], atrial fibrillation [4], and atherosclerotic disease [5], increase the risk of later development of AD. These risk factors are known to be associated with agonist antibodies to key G protein-coupled receptors (GPCR) of the vasculature and autonomic nervous system, such as alpha 1 adrenoceptors (␣ 1 -AR), angiotensin 2 type 1 receptors (AT1R), beta 1 adrenoceptors (␤ 1 -AR), M2 muscarinic receptors (M 2 -MR), and endothelin-1-type A receptors (ET1A) [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer’s Disease

Giil

Kristoffersen

Vedeler

et al. 2015

JAD

View full text Add to dashboard Cite

Abstract.Background: Autoantibodies with agonist function are described in cardiovascular disorders. Since vascular risk factors are associated with an increased risk for Alzheimer's disease (AD), we investigated a potential association between antibodies to the angiotensin 2 type 1 receptor (anti-AT1R) and AD. Objective: The primary objective of this study was to investigate the association between anti-AT1R and AD. The secondary objective was to investigate the association between clinical or biomarker features of AD and anti-AT1R. Methods: Samples from patients with mild AD participating in a longitudinal study in Western Norway (n = 92, 65 [71%] females, mean age 74.8 [range 50-89]) and age-and gender-matched healthy controls (n = 102) were included. Cerebrospinal fluid (CSF) AD biomarkers were assessed in a subgroup of patients. Patients were examined annually, including Mini-Mental State Examination. ELISA was used to measure anti-AT1R in serum. Non-parametric tests were used for statistical calculations and a p < 0.05 was considered significant. Results: AD patients had significantly higher levels of anti-AT1R compared with healthy controls (10.2 U/mL versus 8.1 U/mL, p = 0.04). This difference was found only in patients without hypertension and diabetes. Anti-AT1R levels correlated with CSF total tau (p = 0.03) and phosphorylated tau (p = 0.03) levels, and inversely with blood pressure in AD (Spearman R −0.277, p = 0.008). Discussion: AD is associated with increased levels of anti-AT1R, and the antibodies correlated with CSF total, and phosphorylated tau levels. Further research is needed to understand the blood pressure response in AD without hypertension and a potential link between tau and anti-AT1R in AD.

show abstract

“…Практически важно, что снижение когни-тивных функций отражается на приверженно-сти больных терапии, в т. ч. из-за объективно-го снижения памяти при желании соблюдения врачебных рекомендаций, что подтверждается результатами исследований [37][38], показав-ших связь снижения когнитивных функций с более низкими значениями TTR.…”

Section: Discussionunclassified